Exam #4: Cancer Flashcards
(40 cards)
1
Q
What are the six acquired capabilities of cancer cells?
A
1) Self-sufficiency in growth signals (oncogenes)
2) Insensitivity to antigrowth signals (tumor suppressors)
3) Evading apoptosis (mutation apoptotic pathway)
4) Limitless Replicative Potential (Telomerase)
5) Sustained Angiogenesis
6) Tissue invasion & metastasis
2
Q
Proto-oncogene vs. Oncogene
A
- Proto-oncogenes are genes associated with the control of cell division– they promote growth
- A mutated proto-oncogene is an oncogene causing excessive growth
- Gain of function mutation
- Dominant
- Analogous to gas pedal stuck on
3
Q
Tumor Suppressor Gene & Mutation
A
- Tumor suppressor genes normally inhibit growth
- Mutations inactivate the genes
- Recessive i.e. needs mutation in BOTH alleles
- Analogous to break failure
4
Q
Caretaker Gene & Mutation
A
- Function to protect the integrity of the genome e.g. DNA repair enzymes
- Mutation causes increased accumulation of DNA damage
5
Q
HER2
A
- Family of Epidermal Growth Factor Receptors (tyrosine kinase)
- Mutations convert into oncogene form
- Point mutation allows activation of receptor without ligand
- Generates Neu Oncoprotein
- Implicated in breast cancer
6
Q
Erb1
A
- Family of Epidermal Growth Factor Receptors (tyrosine kinase)
- Mutations convert into oncogene form
- Specifically, mutation deletes ligand binding domain
- Receptor is constitutively active without ligand
- Generates Erb1 Oncoprotein
7
Q
Ras Mutations
A
- G-protein that is normally activated by Sos in the MAP kinase signaling cascade
- Mutations generate a form of Ras that is constitutively active
- Specifically, mutations occur at amino acid positions 12, 13, or 16 & favor GTP binding
- Dominant
- Cancers include pancreas, large intestine, biliary tract, & skin
8
Q
Burkitt’s Lymphoma
A
- B-cell cancer
- Caused by c-Myc rearrangement from chromosome 8 to 14
- c-Myc now near control elements for antibody heavy chain
- Continual production of high levels of Myc in B-cells
9
Q
Two Hit Model
A
- 2 mutations required for tumorigenesis
- 1st mutation in germline (tumor suppressor) is inherited form parents & gives predisposition to cancer
- 2nd somatic mutation is spontaneously & necessary for tumorigenesis
10
Q
Retinoblastoma
A
- Malignancy of the retina seen in childhood
- Gene RB1 encodes Retinoblastoma protein, Rb, that normally inhibits cell cycle progression by binding E2F
- Hereditary vs. Sporadic
- Involved in numerous other cancers
11
Q
p53
A
- Normally unstable, stability increased by ATM/ATR phosphorylation
- Normal instability comes from association with Mdm2, which targets p53 for degradation
- Functions as homotetramer
- Encoded by TP53, most commonly mutated gene in cancer
- dominant negative mutations
12
Q
Li-Fraumeni Syndrome
A
- Heritable condition conferring susceptibility to many forms of cancer
- Dominant inheritance
- Caused by mutant TP53 allele i.e. disabled p53 tetramer
- DNA Damage Repair severely limited
- Early onset tumors, many family members w/ tumors, multiple tumors in individual
13
Q
HPV protein E6
A
- HPV is the most common cause of cervical cancer
- Viral protein E6 inhibits p53 by targeting for ubiquitination
14
Q
HPV protein E7
A
- HPV is the most common cause of cervical cancer
- Viral protein E7 inhibits p53 by targeting for ubiquitination
15
Q
Neurofibromatosis 1
A
- Characterized by cafe au lait spots i.e. multiple non-malignant peripheral nerve tumors
- Caused by a loss of function mutation of NF1 gene, which encodes for the protein, neurofibromin
16
Q
NF1 gene & neurofibromin: normal function
A
- NF1 encodes for the protein neurofibromin
- Neurofibromin accelerated GTP hydrolysis by Ras
- Lack of NF1 gene prolongs Ras signaling
17
Q
BRCA1 & BRCA2
A
- Function in DNA repair by repairing ds-DNA breaks
- Also contribute to homologous recombination
18
Q
Epigenetic Change
A
- any process that alters gene activity without changing the DNA sequence AND leads to modifications that can be transmitted to the cell’s progeny
19
Q
Breakage/Fusion/Bridge Cycle
A
- Loss of p53 function prevents cell cycle arrest & initiate cycle
- Lack of telomeres allows fusion of sister chromatids at mitosis
- Resulting chromosome doesn’t separate at mitosis; rather, it breaks
- Cycle continues
- Ultimately cell should experience mitotic catastrophe and die
20
Q
HIF-1aB
A
- Oxygen sensitive transcription factor
- Regulates the expression of VEGF, vascular endothelial growth factor
21
Q
HIF-1aB Regulation
A
- Oxygen mediated
- Normoxia= HIF-1a is hydroxylated, ubiquitinated, & destoryed i.e. NO HIF-1B
- Hypoxia= HIF-1a not hydroxylated, pairs with HIF-1B, activates transcription factors for angiogenesis (VEGF)
22
Q
Outline the steps of Metastasis
A
1) Invasion of Basement Membrane (E-Cadherin breakdown & Secretion of MMPs)
2) Passage through ECM (breakdown of collagen IV & laminin)
3) Intravasation & Immune System Avoidance
4) Adhesion to basement membrane
5) Extravastion
6) Metastatic Deposit
7) Angiogenesis
8) Growth
23
Q
Familial Adenomatous Polyposis (FAP)
A
- Inherited condition where patients develop adenomatous polyps in colon (benign)
- Develops into colorectal adenocarcinoma without prophylactic colectomy
- Due to mutation of APC gene
24
Q
APC & WNT signaling in FAP
A
- APC gene normally encodes tumor suppressor, APC, which also ensures correct attachment of microtubules to kinetochore
- APC down-regulates WNT
- Without APC, WNT simulates expression of cyclin D, Myc, & other growth promoting genes through B-Catenin
25
Familial Nonpolyposis colorectal carcinoma (HNPCC)
- Hereditary susceptibility to colon cancer
- Defective DNA mismatch repair from mutations in MSH2 or MLH1 genes
- Patient's inherit one defective allele, and get second later
26
Philadelphia Chromosome
- Reciprocal translocation between chromosomes 9 & 22
- Fuses BCR & ABL genes together
- ABL normally endcodes tyrosine kinase
- BCR-ABL tyrosine kinase is constitutively active
- Characteristic of Chronic Myelogenous Leukemia
27
Chronic Myeloid Leukemia
- Caused by BCR-ABL kinase action in hematopoietic cells of the bone marrow, causing expansion of white blood cells
28
Imatinib Mesylate
- Specific BCR-ABL kinase inhibitor
| - Treatment for CML
29
Trastuzumab
- Monoclonal antibody that binds extracellular domain of HER2/Neu
- HER2/Neu expression is prominent in some breast cancers
- Trastuzumab has potent anti-tumor effects
30
Why do normal cells divide a certain number of times and then enter senescence?
- In somatic cells, telomerase (extends telomere) is not expressed in high quantity
- Therefore, with each division, the telomere shortens
- After ~70 divisions short telomeres are recognized as ds-DNA breaks, and p53 mediates cell cycle arrest
31
What two things does conversion of a proto-oncogene to an oncogene do?
- Promote excess protein production
| - Deregulate function
32
c-Fos & c-Myc
- Transcription factors that activate genes that drive cell cycle progression, specifically cyclins
- Normally unstable mRNA & proteins
- Mutations stabilize c-fos
- Chromosomal Rearrangement deregulates c-Myc
33
Hereditary Breast & Ovarian Cancer Syndrome (HBOC)
- Inherited in autosomal dominant manner
- One defective copy of either BRCA1 or BRCA2 increased risk of breast or ovarian cancer
- Loss of second copy causes cancer (Two hit)
34
BRCA1 vs. BRCA2
- BRCA1 participates in homologous recombination & DNA repair via interactions with ATM
- BRCA2 only participates in homologous recombination
35
Increased methylation
- Silences transcription
| - Reduce tumor suppressor expression
36
Decreased methylation
- Activates transcription
| - Increase production of oncoprotein
37
What allows tumor cells to exit the breakage/fusion/bridge cycle?
Re-expression of telomerase
38
VEGF
- Vascular Endothelial Growth Factor
- Activated by HIF-1a/B
- Function to develop an angiogenic gradient
39
MSH2
- DNA mismatch repair gene
| - protein identifies mismatches
40
MLH1
- DNA mismatch repair gene
| - protein repairs DNA
